EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures in a Real-Life Setting: A Prospective, Observational Study in Europe

Bernhard J Steinhoff, Jakob Christensen, Colin P Doherty, Marian Majoie, Anne-Liv Schulz, Fiona Brock, Dimitrios Bourikas, Iryna Leunikava, Anna Kelemen, Eduardo Rubio-Nazabal

Neurology and Therapy · 2025-04 · 14 (2) · 627-642

DOI: 10.1007/s40120-024-00697-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 20.02.2025. Verfasst von Bernhard J Steinhoff und 9 weiteren Autor:innen. Beteiligte Einrichtung: Kork Epilepsy Centre, Landstr. 1, 77694, Kehl-Kork, Germany. bsteinhoff@epilepsiezentrum.de. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Efficacy/tolerability of adjunctive brivaracetam (BRV) for focal-onset seizures (FOS) in patients aged ≥ 16 years was established in randomized controlled trials. This study aimed to evaluate the effectiveness of adjunctive BRV in patients (≥ 16 years) with FOS with/without focal to bilateral tonic-clonic seizures in daily clinical practice. METHODS: A 12-month, prospective, real-world, noninterventional study in nine European countries (EP0077/NCT02687711). BRV was prescribed per clinical practice and European Summary of Product Characteristics. Eligible patients had never received BRV before inclusion. Treating physicians made the decision to prescribe BRV, independently of study participation. Primary effectiveness outcome: BRV retention rate at 12 months; secondary effectiveness outcomes: 50% responder rate, seizure freedom. RESULTS: A total of 544 patients received ≥ 1 BRV dose (mean age: 43.6 years; 52.8% female; mean time since diagnosis: 22.7 years). Patients had a mean of 7.3 lifetime antiseizure medications (ASMs) and median of 3.7 FOS/28 days during 3-month retrospective baseline. Median total ASM drug load (including BRV) was 3.0 at BRV initiation (n = 539) and 3.3 at study end (n = 314). At 12 months, 57.7% of 541 patients remained on BRV, 60.4% of 230 were responders (≥ 50% seizure reduction since baseline), and 13.8% of 269 were seizure-free since BRV initiation. Historical levetiracetam use appeared not to impact retention rate (56.6% of 320 and 59.3% of 221 patients with and without historical levetiracetam use, respectively). 36.0% of 544 patients had drug-related treatment-emergent adverse events (TEAEs), mostly (≥ 5% of patients) drug ineffective (11.4%) and seizure (6.3%). The three most common drug-related TEAEs leading to permanent BRV discontinuation (of 544 patients) were drug ineffective (10.1%), seizure (5.1%), and behavior disorder (3.3%). CONCLUSIONS: Adjunctive BRV was effective in clinical practice in patients with predominantly difficult-to-treat FOS, as shown by BRV retention rate of 57.7% at 12 months, which is in line with real-world retention rates for other new-generation ASMs.

Schlagwörter

Stichwörter der Autor:innen

AdjunctiveAdolescentBrivaracetamEffectivenessEpilepsyFocal-onset seizureNoninterventionalObservationalReal-worldTolerability

Autor:innen und Institutionen

  • Kork Epilepsy Centre, Landstr. 1, 77694, Kehl-Kork, Germany. bsteinhoff@epilepsiezentrum.de.
  • Clinic for Neurology and Neurophysiology, University of Freiburg, Breisacher Str. 64, 79106, Freiburg, Germany. bsteinhoff@epilepsiezentrum.de.
  • Department of Neurology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, 8200, Aarhus N, Denmark.
  • Trinity College Dublin, 152-160 Pearse Street, Dublin, D02 R590, Ireland.
  • FutureNeuro, SFI Research Centre, RCSI, 123 St. Stephen's Green, Dublin, D02 YN77, Ireland.
  • Academic Center of Epileptology Kempenhaeghe, Maastricht University Medical Center, Sterkselseweg 65, 5591 VE, Heeze, Netherlands.

Förderung

  • UCB

Zitieren

APA

Steinhoff, B. J., Christensen, J., Doherty, C. P., Majoie, M., Schulz, A. L., Brock, F., Bourikas, D., Leunikava, I., Kelemen, A., & Rubio-Nazabal, E. (2025). Effectiveness During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures in a Real-Life Setting: A Prospective, Observational Study in Europe. Neurology and Therapy, 14(2), 627-642. https://doi.org/10.1007/s40120-024-00697-4

Vancouver

Steinhoff BJ, Christensen J, Doherty CP, Majoie M, Schulz AL, Brock F, et al. Effectiveness During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures in a Real-Life Setting: A Prospective, Observational Study in Europe. Neurology and Therapy. 2025;14(2):627-642. doi:10.1007/s40120-024-00697-4

BibTeX
@article{Steinhoff2025,
  author = {Steinhoff, Bernhard J and Christensen, Jakob and Doherty, Colin P and Majoie, Marian and Schulz, Anne-Liv and Brock, Fiona and Bourikas, Dimitrios and Leunikava, Iryna and Kelemen, Anna and Rubio-Nazabal, Eduardo},
  title = {Effectiveness During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures in a Real-Life Setting: A Prospective, Observational Study in Europe},
  journal = {Neurology and Therapy},
  year = {2025},
  volume = {14},
  number = {2},
  pages = {627--642},
  doi = {10.1007/s40120-024-00697-4}
}
Kostenlos starten →